The reiteration of a Neutral rating and maintenance of a $21 price target by Wedbush suggests a stable outlook for Regenxbio's stock in the short term. The analyst's view likely reflects an assessment of the company's current valuation and future prospects that neither strongly favors buying nor selling the stock. This analysis could influence investor sentiment by reinforcing a wait-and-see approach.